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INSTRUCTIONS TO AUTHORS
The Journal of the Chinese Medical Association (JCMA) is the official peer-reviewed and SCIE-indexed publication of the Chinese 
Medical Association, which is based in Taipei, Taiwan. The Journal is published every month by Elsevier.
Authors are welcome to submit original contributions relating to all fields of medicine and allied  
disciplines that are of interest to the medical profession.The Editorial Board requires authors to be in compliance with the 
Uniform Requirements for Manuscripts Submitted to Biomedical 
Journals (URMs), which are compiled by the International 
Committee of Medical Journal Editors (ICMJE); current URMs are 
available at http://www.icmje.org. These Instructions to Authors are 
revised periodically by the Editors as needed. Authors should consult 
www.jcma-online.com for the latest version of these instructions. Any 
manuscript not prepared according to these instructions will be 
returned immediately to the author(s) without review.
1. Manuscript Submission
Manuscripts should be submitted by one of the below methods only.
1.1. Online Submission
Manuscripts (meaning all submission items, including all text, tables, 
artwork, cover letter, conflicts of interest disclosures, and any other 
required documents/material) may be submitted online to the JCMA 
through the Elsevier Editorial System (EES) at http://ees.elsevier.
com/jcma. This site will guide authors stepwise through the submis-
sion process. If assistance is required, please refer to the tutorials 
for authors and/or customer support that are available on the EES 
website; you may also contact the Editorial Office.
Editorial Office
Journal of the Chinese Medical Association
Chinese Medical Association
Taipei Veterans General Hospital
201, Section 2, Shih-Pai Road
Taipei 112, Taiwan, R.O.C.
Tel: (+886) (0)2 2871-2121 ext. 3043
Fax: (+886) (0)2 2877-1873
E-mail: jcma@vghtpe.gov.tw
1.2. Other Methods of Submission
If you are unable to submit your manuscript via the EES, you may 
submit your manuscript and related submission items as e-mail attach-
ments to the JCMA Editorial Office.
Alternatively, you can submit your material on a CD-R and post it, 
together with 4 hard copies of your manuscript (that match the disk 
file exactly) and a copy of each of the required supporting documents, 
to the Editorial Office.
1.3. Important Information
l  Articles should be in Microsoft Word document format and pre-
pared in the simplest form possible. We will add in the correct font, 
font size, margins and so on according to the Journal’s style.
l  You may use automatic page numbering, but do NOT use other 
kinds of automatic formatting such as footnotes, headers and 
footers. References especially should NOT be formatted using the 
MS Word “endnotes” or “footnotes” function; instead, you may 
use the commercially available EndNote® or Reference Manager® 
software to manage your references.l  Put text, references, table headings and tables, and figure legends in 
one file.
l  Figures must be submitted as separate picture files, at the correct 
resolution and named according to the figure number and format, 
e.g., “Fig1.tif”, “Fig2.jpg”. Please see Section 9.8. for more 
information.
1.4. Supporting Documents
The following documents must be included in your submission (refer 
also to the Checklist that follows these author instructions). Items (1), 
(2) and (3) are mandatory. Items (4), (5), (6) and (7) are required 
only if they are applicable to your manuscript.
(1)  Cover Letter. This must include the following information: 
•	 title of the manuscript
•	  names (spelled out in full) of all the authors*, and the 
institutions with which they are affiliated; indicate all 
affiliations with a superscripted lowercase letter after the 
author’s name and in front of the matching affiliation 
(*the name of each author should be written with the family 
name last, e.g., Wan-Lin Chang)
•	  corresponding author details (name, e-mail, mailing 
address, telephone and fax numbers)
•	 e-mail address of the first author
•	  a statement that the material contained in the manuscript 
has not been previously published and is not being 
concurrently submitted elsewhere
•	  persons who do not fulfill the requirements to be listed as 
authors but who nevertheless contributed to the 
manuscript (such as those who provided writing 
assistance, for example) should be disclosed
•	  list of manuscripts that have been published, submitted, 
or are in press that are similar to the submission to the 
JCMA (and include in your submission copies of those 
similar manuscripts so that JCMA Editors can be assured 
there is no overlap)
•	  your signature and those of ALL your coauthors
•	  Optional: if you have a list of reviewers who you wish to 
review or not to review your manuscript, you may include 
this list in the cover letter
(2)  Authorship & Conflicts of Interest Statement. Each author’s con-
tribution to the manuscript should be listed. Any and all potential 
and actual conflicts of interest should also be listed (see Section 2 
for more information). Please use the JCMA Authorship & 
Conflicts of Interest Statement form that follows these author 
instructions and that is also provided on the Journal's website at 
www.jcma-online.com. Your signature and those of ALL your 
coauthors must be included.
(3)  Copyright Transfer Agreement. In the event that your manuscript 
is accepted for publication in the JCMA, you are required to 
transfer all copyright ownership in and relating to the work to the 
Chinese Medical Association and Elsevier. Please use the JCMA 
Copyright Transfer Agreement form that follows these author 
instructions and that is also provided on the Journal’s website at 
www.jcma-online.com. Your signature and those of ALL your 
coauthors must be included.
(4)  Ethics Statement. Articles covering the use of human or animal 
samples in research, or human or animal experiments must be 
accompanied by a letter of approval from the relevant review 
committee or authorities. See Section 3 for more information.
(5)  Consolidated Standards of Reporting Trials (CONSORT) flow 
chart for randomized controlled trials submitted for publication. 
See Section 4 for more information.
(6)  Signed Statement of Informed Consent. Articles where human 
subjects can be identified in descriptions, photographs or pedi-
grees must be accompanied by a signed statement of informed 
consent to publish (in print and online) the descriptions, 
photographs and pedigrees from each subject who can be 
identified. See Section 5 for more information.
(7)  Copyright Permission. If you have reproduced or adapted mate-
rial from other copyrighted sources, the letter(s) of permission 
from the copyright holder(s) to reproduce or adapt the copy-
righted sources must be supplied. Otherwise, such material must 
be removed from your manuscript.
2. Disclosure of Conflicts of Interest
A conflict of interest occurs when an individual’s objectivity is poten-
tially compromised by a desire for financial gain, prominence, profes-
sional advancement or a successful outcome. JCMA Editors strive to 
ensure that what is published in the Journal is as balanced, objective 
and evidence-based as possible. Since it can be difficult to distinguish 
between an actual conflict of interest and a perceived conflict of inter-
est, the Journal requires authors to disclose all and any potential 
conflicts of interest.
Conflicts of interest may be financial or non-financial. 
Financial conflicts include financial relationships such as hono-
raria; educational grants; participation in speakers’ bureaus; 
membership, employment, consultancies, stock ownership, or 
other equity interest; expert testimony or patent-licensing 
arrangements. Non-financial conflicts include personal or profes-
sional relationships, affiliations, academic competition, intellec-
tual passion, knowledge or beliefs that might affect objectivity.
Please ensure that the name of each author listed in your 
manuscript appears in either Section I or Section II of the JCMA 
Conflicts of Interest Statement form (an author’s name cannot 
appear in both Section I and Section II of the form).
3. Ethical Approval of Studies and Informed Consent
For human or animal experimental investigations, appropriate institu-
tional review board or ethics committee approval is required, and such 
approval should be stated in the methods section of the manuscript. 
For those investigators who do not have formal ethics review commit-
tees, the principles outlined in the Declaration of Helsinki should be 
followed (World Medical Association. Declaration of Helsinki: ethical 
principles for medical research involving human subjects. Available at: 
http://www.wma.net/en/30publications/10policies/b3/17c.pdf).For investigation of human subjects, state explicitly in the meth-
ods section of the manuscript that informed consent was obtained 
from all participating adult subjects and from parents or legal guardi-
ans for minors or incapacitated adults, together with the manner in 
which informed consent was obtained (e.g., oral or written).
For work involving animals, the guidelines for their care and 
use that were followed should be stated in the methods section of 
the manuscript. For those investigators who do not have formal 
institutional guidelines relating to animal experiments, the 
European Commission Directive 86/609/EEC for animal experi-
ments (available at http://ec.europa.eu/environment/
chemicals/lab_animals/legislation_en.htm) should be followed 
and the same should be stated in the methods section of the man-
uscript.
4. Reporting Clinical Trials
All randomized controlled trials submitted for publication should 
include a completed Consolidated Standards of Reporting Trials 
(CONSORT) flow chart (please go to http://www.consort- 
statement.org for more information). The JCMA has adopted the 
ICMJE proposal that requires, as a condition of consideration for 
publication of clinical trials, registration in a public trials registry. 
Purely observational studies (those in which the assignment of the 
medical intervention is not at the discretion of the investigator) will 
not require registration. Further information can be found at http://
www.icmje.org.
5. Identification of Patients in Descriptions, 
Photographs and Pedigrees
A signed statement of informed consent to publish (in print and 
online) patient descriptions, photographs and pedigrees should 
be obtained from all persons (parents or legal guardians for 
minors) who can be identified (including by the patients them-
selves) in such written descriptions, photographs or pedigrees. 
Such persons should be shown the manuscript before its 
submission. Omitting data or making data less specific to de-
identify patients is acceptable, but changing any such data is not 
acceptable. State explicitly in the methods section of the manu-
script that informed consent was obtained from all participating 
adult subjects or from parents or legal guardians for minors or 
incapacitated adults, together with the manner in which 
informed consent was obtained (i.e., oral or written).
6. Previous Publication or Duplicate Submission
Submitted manuscripts are considered with the understanding that 
they have not been published previously in print or electronic format 
(except in abstract or poster form) and are not under consideration in 
totality or in part by another publication or electronic medium.
7. Basic Criteria
Articles should be written in English, using American English spelling, 
and meet the following basic criteria: the material is original, the infor-
mation is important, the writing is clear and concise, the study meth-
ods are appropriate, the data are valid, and the conclusions are 
reasonable and supported by the data.
8. Article Categories
The categories of articles that are published in the Journal are listed 
and described below. Please select the category that best describes 
your paper. If your paper does not fall into any of these categories, 
please contact the Editorial Office.
8.1. Editorials
These are usually written by invited authors or editorial board mem-
bers and are comments on recent news or articles published in the 
Journal. Typical length: no more than 1200 words and not more than 
15 references.
8.2. Review Articles
These should aim to provide the reader with a balanced overview of an 
important and topical issue in research or clinical practice. They should 
cover aspects of a topic in which scientific consensus exists as well as 
aspects that remain controversial and are the subject of ongoing scien-
tific research. All articles and data sources reviewed should include 
information about the specific type of study or analysis, population, 
intervention, exposure, and tests or outcomes. All articles or data 
sources should be selected systematically for inclusion in the review 
and critically evaluated. Figures, tables, algorithms and other forms of 
illustration should be included as appropriate.
Although many of the Review Articles published in the 
Journal are usually written by invited authors who are recognized 
experts on that particular topic, unsolicited Reviews are welcome 
and will be given due consideration.
Typical length: abstract, no more than 300 words; main text, 
no more than 3500 words and not more than 100 references.
8.3. Original Articles
These articles typically include randomized trials, intervention studies, 
studies of screening and diagnostic tests, laboratory and animal stud-
ies, cohort studies, cost-effectiveness analyses, case-control studies, 
and surveys with high response rates, which represent new and signifi-
cant contributions to the field.
Section headings should be: Abstract, Introduction, Methods, 
Results, Discussion, Conflicts of Interest Statement (if any), 
Acknowledgments (if any), and References.
The Introduction should provide a brief background to the 
subject of the paper, explain the importance of the study, and 
state a precise study question or purpose.
The Methods section should describe the study design and 
methods (including the study setting and dates, patients/
participants with inclusion and exclusion criteria, patient samples 
or animal specimens used, the essential features of any 
interventions, the main outcome measures, the laboratory 
methods followed, or data sources and how these were selected 
for the study), and state the statistical procedures employed in 
the research.
The Results section should comprise the study results pre-
sented in a logical sequence, supplemented by tables and/or fig-
ures. Take care that the text does not repeat data that are 
presented in tables and/or figures. Only emphasize and summa-
rize the essential features of the main results.The Discussion section should be used to emphasize the new 
and important aspects of the study, placing the results in context 
with published literature, the implications of the findings, and 
the conclusions that follow from the study results.
Typical length: structured abstract, no more than 300 words; 
main text, no more than 3000 words and not more than 60 
references.
8.4. Case Reports
These are short discussions of a case or case series with unique 
features not previously described that make an important teaching 
point or scientific observation. They may describe novel techniques 
or use of equipment, or new information on diseases of importance. 
Section headings should be: Abstract, Introduction, Case Report, 
Discussion, Conflicts of Interest Statement (if any), 
Acknowledgments (if any), and References.
The Introduction should describe the purpose of the present 
report, the significance of the disease and its specificity, and briefly 
review the relevant literature.
The Case Report should include statements of the problem, 
patient history, diagnosis, treatment, outcome and any other 
information pertinent to the case(s).
The Discussion should compare, analyze and discuss the 
similarities and differences between the reported case and similar 
cases reported in other published articles. The importance or 
specificity of the case should be restated when discussing the 
differential diagnoses. Suggest the prognosis of the disease and 
possibility of prevention.
Case reports should have no more than 6 authors. Typical 
length: abstract, no more than 200 words; main text, no more 
than 1200 words and not more than 20 references.
Authors should note that case reports are subject to the pay-
ment of peer-review fees and publication charges; please see 
Section 12 for more information.
8.5. Brief Communications
These may be prepared according to the format of Original Articles, 
but are expected to be concise presentations of preliminary experi-
mental results, instrumentation and analytical techniques, or aspects of 
clinical or experimental practice that are not fully investigated, verified 
or perfected but which may be of widespread interest or application. 
The Editors reserve the right to decide what constitutes a Brief 
Communication.
Brief communications should have no more than 6 authors. 
Typical length: abstract, no more than 200 words; main text, no 
more than 1200 words and not more than 40 references.
8.6. Letters to the Editor
Brief letters of constructive comments in response to previously 
published JCMA articles are welcome. Letters should have a title, 
no more than 4 authors, be no longer than 500 words, and may 
include up to 10 references. Ensure that the corresponding 
author’s mailing and e-mail addresses are included. Letters are 
edited, sometimes extensively, to sharpen their focus. They may 
be sent for peer review at the discretion of JCMA Editors. Letters 
are selected based on clarity, significance, and space.
9. Manuscript Preparation
Text should be typed double-spaced on white A4 (297  210 mm) 
paper, with outer margins of 2.5 cm. The manuscript should include a 
title page, abstract, keywords, text, conflicts of interest statement (if 
any), acknowledgments (if any), references, and figures and tables as 
appropriate. Each section of the manuscript should begin on a new 
page. Pages should be numbered consecutively, beginning with the 
title page.
9.1. Title Page
The title page should contain the following information (in order, 
from the top to bottom of the page):
l article category
l article title
l  IMPORTANT: please do NOT include any author names 
and affiliations or corresponding author information on the title 
page (this information should be listed in your cover 
letter instead) because the JCMA follows a double-blind peer 
review process
9.2. Abstract and Keywords
An abstract and 3–5 relevant keywords (in alphabetical order) are 
required for the following article categories: Review Articles, Original 
Articles, Case Reports and Brief Communications.
Abstracts for Original Articles should be structured into the 
sections listed below and be no more than 300 words long.
Background: briefly explain the importance of the study topic 
and state a precise study question or purpose.
Methods: briefly introduce the methods used to perform the 
study; include information on the study design, setting, subjects, 
interventions, outcome measures and analyses as appropriate.
Results: briefly present the significant results, with data and statis-
tical details such as p values where appropriate; be sure that informa-
tion in the abstract matches that in the main text.
Conclusion: state the meaning of your findings, being careful 
to address the study question directly and to confine your con-
clusions to aspects covered in the abstract; give equal emphasis to 
positive and negative findings.
Abstracts for Case Reports should be unstructured (in one 
single paragraph with no section headings), no more than 200 
words long, and include the significance and purpose of the case 
presentation, the diagnostic methods of the case, the key data, 
and brief comments and suggestions with regard to the case.
Abstracts for Review Articles (not more than 300 words) 
and Brief Communications (not more than 200 words) should 
also be unstructured (in one single paragraph with no section 
headings).
Keywords should be taken from the Medical Subject 
Headings (MeSH) list of Index Medicus (http://www.nlm.nih.
gov/mesh/meshhome.html).
No abstract or keywords are required for Editorials and 
Letters to the Editor.
9.3. Main Text
No author information such as names, affiliations and contact infor-
mation should appear in the main text. The text for Original Articles 
and Brief Communications should be organized into the following 
sections: Introduction, Methods, Results, Discussion, Conflicts of 
Interest Statement (if any), Acknowledgments (if any), and References. Subheadings in long papers are acceptable if needed for clarification 
and ease of reading. Sections for Case Reports are: Introduction, Case 
Report, Discussion, Conflicts of Interest Statement (if any), 
Acknowledgments (if any), and References. Each section should begin 
on a new page.
9.3.1. Abbreviations
Where a term/definition will be continually referred to, it must be 
written in full when it first appears in the text, followed by the subse-
quent abbreviation in parentheses. Thereafter, the abbreviation may 
be used. An abbreviation should not be first defined in any section 
heading; if an abbreviation has previously been defined in the text, 
then the abbreviation may be used in a subsequent section heading. 
Restrict the number of abbreviations to those that are absolutely 
necessary.
9.3.2. Numbers
Numbers that begin a sentence or those that are less than 10 should 
be spelled out using letters. Centuries and decades should be spelled 
out, e.g., the Eighties or nineteenth century. Laboratory parameters, 
time, temperature, length, area, mass, and volume should be expressed 
using digits.
9.3.3. Units
Système International (SI) units must be used, with the exception of 
blood pressure values which are to be reported in mmHg. Use the 
metric system for the expression of length, area, mass, and volume. 
Temperatures are to be given in degrees Celsius.
9.3.4. Names of drugs, devices and other products
Use the Recommended International Non-proprietary Name 
(rINN) for medicinal substances, unless the specific trade name of a 
drug is directly relevant to the discussion. Generic drug names should 
appear in lowercase letters in the text. If a specific proprietary drug 
needs to be identified, the brand name may appear only once in the 
manuscript in parentheses following the generic name the first time 
the drug is mentioned in the text.
For devices and other products, the specific brand or trade name, 
the manufacturer and their location (city, state, country) should be 
provided the first time the device or product is mentioned in the text, 
for example, “…SPSS version 11 was used (SPSS Inc., Chicago, IL, 
USA)”. Thereafter, the generic term (if appropriate) should be used.
9.3.5. Gene nomenclature
Current standard international nomenclature for genes should be 
adhered to. For human genes, use genetic notation and symbols 
approved by the HUGO Gene Nomenclature Committee (http://
www.genenames.org). You may also refer to the resources available on 
PubMed at http://www.ncbi.nlm.nih.gov/guide/genes-expression. 
The Human Genome Variation Society has a useful site that provides 
guidance in naming mutations at http://www.hgvs.org/mutnomen/
index.html. In your manuscript, genes should be typed in italic font 
and include the accession number.
9.3.6. Statistical requirements
Statistical analysis is essential for all research papers except Case 
Reports. Use correct nomenclature for statistical methods (e.g., two 
sample t test, not unpaired t test). Descriptive statistics should follow 
the scales used in data description. Inferential statistics are important 
for interpreting results and should be described in detail.
All p values should be presented to the third decimal place for 
accuracy. The smallest p value that should be expressed is p < 
0.001 since additional zeros do not convey useful information; 
the largest p value that should be expressed is p > 0.99.
9.3.7. Personal communications and unpublished data
These sources cannot be included in the references list but may 
be described in the text. The author(s) must give the full name 
and highest academic degree of the person, the date of the com-
munication, and indicate whether it was in oral or written (letter, 
fax, e-mail) form. A signed statement of permission should be 
included from each person identified as a source of information 
in a personal communication or as a source for unpublished data.
9.4. Conflicts of Interest Statement and/or Funding/
Support Statement
Since it is difficult to distinguish between an actual conflict of 
interest and a perceived conflict of interest, the JCMA requires 
authors to disclose all and any potential conflicts of interest and 
let readers judge for themselves. Therefore, please ensure that 
you provide information about any potential financial and non-
financial conflicts of interest (see Section 2 for more information) 
in a concise paragraph after the main text.
All financial and material support for the research, work, writ-
ing and editorial assistance from internal or external agencies, 
including commercial companies, should be clearly and com-
pletely identified in a Funding/Support Statement.
9.5. Acknowledgments
After the Conflicts of Interest Statement and/or Funding/
Support Statement, general acknowledgments for consultations 
and statistical analyses should be listed concisely, including the 
names of the individuals who were directly involved. Consent 
should be obtained from those individuals before their names are 
listed in this section. Those acknowledged should not include 
secretarial, clerical or technical staff whose participation was 
limited to the performance of their normal duties.
9.6. References
Authors are responsible for the accuracy and completeness of their 
references and for correct in-text citation.
9.6.1. In the main text, tables and figure legends
l  References should be indicated by superscripted numbers according 
to order of appearance in the text, and placed after punctuation. 
[The actual authors can be referred to, but the reference number(s) 
must always be given.]
l  References cited in tables or figure legends should be included 
in sequence at the point where the table or figure is first men-
tioned in the main text.
l  Do not cite abstracts unless they are the only available refer-
ence to an important concept.
l  Do not cite uncompleted work or work that has not yet been 
accepted for publication (i.e., “unpublished observation”, 
“personal communication”) as references. Also see Section 
9.3.7.9.6.2. In the references list
l  References should be compiled at the end of the manuscript accord-
ing to the order of citation in the text.
l  References should be limited to those cited in the text only.
l  Journal references should include, in order, authors’ surnames and 
initials, article title, abbreviated journal name, year, volume and 
inclusive page numbers.
l  The surnames and initials of all the authors up to 6 should be 
included, but when authors number 7 or more, list the first 6 
authors only followed by “et al”.
l  Abbreviations for journal names should conform to those used in 
MEDLINE.
l  If citing a website, provide the author information, article title, web-
site address and the date you accessed the information.
l  Reference to an article that is in press must state the journal name 
and, if possible, the year and volume.
Examples of the most common reference types are provided below. 
(Please pay particular attention to the formatting, word capitalization, 
spacing and style.)
Standard journal articles
Luo CB, Teng MM, Chang FC, Lin CJ, Guo WY, Chang CY. Stent-
assisted coil embolization of intracranial aneurysms: a single center 
experience. J Chin Med Assoc 2012;75:322–8.
Huang HK, Chiang CC, Hung SH, Su YP, Chiu FY, Liu CL, et al. 
The role of autologous bone graft in surgical treatment of hyper-
trophic nonunion of midshaft clavicle fractures. J Chin Med Assoc 
2012;75:216–20.
Journal supplement
Kaplan NM. The endothelium as prognostic factor and therapeutic 
target: what criteria should we apply? J Cardiovasc Pharmacol 
1998;32(Suppl 3):S78–80.
Journal article not in English but with English abstract
Hofele C, Schwager-Schmitt M, Volkmann M. Prognostic value of 
antibodies against p53 in patients with oral squamous cell carci-
noma—five years survival rate. Laryngorhinootologie 2002;81:342–5. 
[In German, English abstract]
Book with edition
Bradley EL. Medical and surgical management. 2nd ed. Philadelphia: 
Saunders; 1982.
Book with editors
Letheridge S, Cannon CR, editors. Bilingual education: teaching 
English as a second language. New York: Praeger; 1980.
Book chapter in book with editor and edition
Greaves M, Culligan DJ. Blood and bone marrow. In: Underwood 
JCE, editor. General and systematic pathology. 4th ed. London: 
Churchill Livingstone; 2004, p. 615–72.
Book series with editors
Wilson JG, Fraser FC, editors. Handbook of teratology, vols. 1–4. New 
York: Plenum Press; 1977–1978.
Bulletin
World Health Organization. World health report 2002: reducing risk, 
promoting healthy life. Geneva, Switzerland: World Health 
Organization; 2002.
Electronic publications
Duchin JS. Can preparedness for biological terrorism save us from 
pertussis? Arch Pediatr Adolesc Med 2004;158(2). Available at 
http://archpedi.ama-assn.org/cgi/content/full/158/2/106. 
Accessed June 12, 2004.
Smeeth L, Iliffe S. Community screening for visual impairment in the 
elderly. Cochrane Database Syst Rev 2002(2):CD001054. 
Doi:10.1002/14651858.CD1001054.
Item presented at a meeting but not yet published
Khuri FR, Lee JJ, Lippman SM. Isotretinoin effects on head and neck 
cancer recurrence and second primary tumors. In: Proceedings from 
the American Society of Clinical Oncology, May 31–June 3, 2003; 
Chicago, IL, abstract 359.
Item presented at a meeting and published
Cionni RJ. Color perception in patients with UV- or bluelight-filter-
ing IOLs. In: Symposium on cataract, IOL, and refractive surgery. San 
Diego, CA: American Society of Cataract and Refractive Surgery; 
2004, abstract 337.
Thesis
Ayers AJ. Retention of resin restorations by means of enamel etching and 
by pins. MSD thesis, Indiana University School of Dentistry, 
Indianapolis, 1971.
Website
Glueckauf RL, Whitton J, Baxter J. Videocounseling for families of 
rural teens with epilepsy—project update. Telehealth News 1998. 
Available at http://www.telehealth.net/subscribe/newslettr_4a.
html#1. Accessed November 15, 2008.
Company/manufacturer publications/pamphlets
Eastman Kodak Company, Eastman Organic Chemicals. Catalog no. 
49. Rochester, NY: Eastman Kodak; 1977, p. 2–3.
ZstatFlu. Package insert. Oklahoma City, OK: ZymeTx Inc; 2000.
9.7. Tables
Tables should supplement, not duplicate, the text. They should 
have a concise table heading, be self-explanatory, and numbered 
consecutively in the order of their citation in the text. Items 
requiring explanatory footnotes should be denoted using super-
scripted lowercase letters (a, b, c, etc.), with the footnotes 
arranged under the table in alphabetical order. Asterisks (*, **) 
are used only to indicate the probability level of tests of signifi-
cance. Abbreviations used in the table must be defined and placed 
after the footnotes in alphabetical order. If you include a block 
of data or table from another source, whether published or 
unpublished, you must acknowledge the original source.
9.8. Figures
9.8.1. General guidelines
The number of figures should be restricted to the minimum nec-
essary to support the textual material. Figures should have an informative figure legend and be numbered in the order of their 
citation in the text. All symbols and abbreviations should be 
defined in the figure legend in alphabetical order. Items requir-
ing explanatory footnotes should follow the same style as that for 
tables as described in Section 9.7.
Patient identification should be obscured. All lettering should 
be done professionally and should be in proportion to the draw-
ing, graph or photograph. Photomicrographs must include an 
internal scale marker, and the legend should state the type of 
specimen, original magnification and stain.
Figures must be submitted as separate picture files, at the cor-
rect resolution (see Section 9.8.2.) and named according to the 
figure number and format, e.g., “Fig1.tif”, “Fig2.jpg”.
9.8.2. Formats
Regardless of the application used, when your electronic artwork 
is finalized, please “save as” or convert the images to one of the 
following formats (note the resolution requirements for line draw-
ings, halftones, and line/halftone combinations given below):
l  EPS: vector drawings. Embed the font or save the text as 
“graphics”.
l  TIFF: color or grayscale photographs (halftones)—use a 
minimum of 300 dpi.
l  TIFF: bitmapped line drawings—use a minimum of 1000 
dpi.
l  TIFF: combination of bitmapped line/halftone (color or 
grayscale)—use a minimum of 600 dpi.
l  DOC, XLS or PPT: if your electronic artwork is created in 
any of these Microsoft Office applications, please supply “as 
is”.
Please do not:
l  Supply files that do not meet the resolution requirements 
detailed above;
l  Supply files that are optimized for screen use 
(such as GIF, BMP, PICT, WPG) as the resolution is too 
low;
l  Submit graphics that are disproportionately large for the 
content.
A detailed guide on electronic artwork is available at http://www.
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